Skip to main content
. 2022 Sep 16;101(37):e30397. doi: 10.1097/MD.0000000000030397

Table 3.

Results after treatment of gastric neuroendocrine tumors.

G1 NET G2 NET G3 NET Total P value
(n = 16) (n = 4) (n = 2) (n = 22)
Treatment modality, n (%) <0.01
 EMR 5 (31.3) 1 (16.7) 0 (0) 6 (27.3)
 ESD 7 (43.8) 1 (16.7) 0 (0) 8 (36.4)
 Follow-up 4 (25.0) 0 (0) 0 (0) 4 (18.2)
 Surgical resection 0 (0) 2 (50.0) 2 (100) 4 (18.2)
Tumor size, mm, mean (SD) 4.6 (2.3) 8.0 (3.5) 34.0 (21.0) 7.9 (11.0) 0.02
Depth of invasion, n (%) 0.02
 Mucosa or submucosa 16 (100) 4 (66.7) 0 (0) 20 (90.9)
 Proper muscle or deeper 0 (0) 0 (0) 2 (100) 2 (9.1)
Lymphovascular invasion, n (%) 0 (0) 0 (0) 2 (100) 2 (9.1) 0.02
Lymph node metastasis, n (%) 0 (0) 0 (0) 2 (100) 2 (9.1) 0.02
Distant metastasis, n (%) 0 (0) 0 (0) 2 (100) 2 (9.1) 0.02

G = grade, NET = neuroendocrine tumor, n = number, SD = standard deviation, EMR = endoscopic mucosal resection, ESD = endoscopic submucosal dissection.